



# NEWS RELEASE

## RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN

Milan, 27 April 2010 –Recordati S.p.A. will be hosting a meeting with the financial community and specialized press on:

**Thursday 6 May 2010 at 4 pm  
Palazzo Mezzanotte  
Piazza degli Affari, 6 – Milan**

At the meeting Recordati's First Quarter 2010 results will be presented and the Group's development strategy and objectives for the period 2010-2012 will be discussed.

A simultaneous translation into English of the proceedings will be available via conference call. Dial-in numbers and access ID are:

Italy	+39 02 36005955
UK	+44 (0) 1452587427
USA	+18665516755
France	+33 (0) 170751217
Germany	+49 (0) 6922227071

ID to access the call in the English language: 71717137

Callers are invited to dial-in 10 minutes before conference time. A recording of the conference call will be subsequently placed on the website:

[http://www.recordati.com/rec\\_en/investors/presentations/](http://www.recordati.com/rec_en/investors/presentations/)

*Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe. A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2009 was € 747.5 million, operating income was € 162.2 million and net income was € 110.6 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

### Investor Relations

Marianne Tatschke  
(39)0248787393

e-mail: [inver@recordati.it](mailto:inver@recordati.it)

### Media Relations

Claudio Rossetti (Echo Comunicazione d'Impresa)  
(39)02 62694736

e-mail: [crossetti@echocom.it](mailto:crossetti@echocom.it)